Focal Nature of Neurological Disorders Necessitates Isotype-Selective Histone Deacetylase (HDAC) Inhibitors
Histone deacetylase (HDAC) inhibitors represent a promising new avenue of therapeutic options for a range of neurological disorders. Within any particular neurological disorder, neuronal damage or death is not widespread; rather, particular brain regions are preferentially affected. Different disord...
Gespeichert in:
| Veröffentlicht in: | Molecular neurobiology 2009-08, Vol.40 (1), p.33-45 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 45 |
|---|---|
| container_issue | 1 |
| container_start_page | 33 |
| container_title | Molecular neurobiology |
| container_volume | 40 |
| creator | Thomas, Elizabeth A. |
| description | Histone deacetylase (HDAC) inhibitors represent a promising new avenue of therapeutic options for a range of neurological disorders. Within any particular neurological disorder, neuronal damage or death is not widespread; rather, particular brain regions are preferentially affected. Different disorders exhibit distinct focal pathologies. Hence, understanding the region-specific effects of HDAC inhibitors is essential for targeting appropriate brain areas and reducing toxicity in unaffected areas. The outcome of HDAC inhibition depends on several factors, including the diversity in the central nervous system expression of HDAC enzymes, selectivity of a given HDAC inhibitor for different HDAC enzymes, and the presence or absence of cofactors necessary for enzyme function. This review will summarize brain regions associated with various neurological disorders and factors affecting the consequences of HDAC inhibition. |
| doi_str_mv | 10.1007/s12035-009-8067-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67404133</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67404133</sourcerecordid><originalsourceid>FETCH-LOGICAL-c435t-a38d0f8094eeaeb1d3388f015c27e6c26ef958ed150bfb380fa545a4f325c6463</originalsourceid><addsrcrecordid>eNp1kU9rFEEQxRtRzCb6AbzI4EH00Nr_p-cYdk12IcSDem56empix9nptatHmG_vLLsQEDwVvPrVq6IeIW84-8QZqz8jF0xqylhDLTM1nZ-RFde6oZxb8ZysmG0krY2yF-QS8ZExITirX5IL3sjGGFmvyK-bFPxQ3fsyZahSX93DlNOQHuJR3kRMuYOMixwAMRZfAKsdpjIfgH6DAUKJf6DaRixphGoDPkCZB49Qfdhurtcfq934M7axpIyvyIveDwivz_WK_Lj58n29pXdfb3fr6zsalNSFemk71lvWKAAPLe-ktLZnXAdRgwnCQN9oCx3XrO1baVnvtdJe9VLoYJSRV-T9yfeQ0-8JsLh9xADD4EdIEzpTK6a4lAv47h_wMU15XG5zgivLVWOPbvwEhZwQM_TukOPe59lx5o4xuFMMbonBHWNw8zLz9mw8tXvonibOf18AcQJwaY0PkJ82_9_1Lx5ik5M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>214814986</pqid></control><display><type>article</type><title>Focal Nature of Neurological Disorders Necessitates Isotype-Selective Histone Deacetylase (HDAC) Inhibitors</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Thomas, Elizabeth A.</creator><creatorcontrib>Thomas, Elizabeth A.</creatorcontrib><description>Histone deacetylase (HDAC) inhibitors represent a promising new avenue of therapeutic options for a range of neurological disorders. Within any particular neurological disorder, neuronal damage or death is not widespread; rather, particular brain regions are preferentially affected. Different disorders exhibit distinct focal pathologies. Hence, understanding the region-specific effects of HDAC inhibitors is essential for targeting appropriate brain areas and reducing toxicity in unaffected areas. The outcome of HDAC inhibition depends on several factors, including the diversity in the central nervous system expression of HDAC enzymes, selectivity of a given HDAC inhibitor for different HDAC enzymes, and the presence or absence of cofactors necessary for enzyme function. This review will summarize brain regions associated with various neurological disorders and factors affecting the consequences of HDAC inhibition.</description><identifier>ISSN: 0893-7648</identifier><identifier>EISSN: 1559-1182</identifier><identifier>DOI: 10.1007/s12035-009-8067-y</identifier><identifier>PMID: 19396637</identifier><language>eng</language><publisher>New York: Humana Press Inc</publisher><subject>Animals ; Biomedical and Life Sciences ; Biomedicine ; Brain - drug effects ; Brain - enzymology ; Brain - pathology ; Brain research ; Cell Biology ; Enzyme Inhibitors - therapeutic use ; Enzymes ; Gene Expression Regulation ; Histone Deacetylase Inhibitors ; Histone Deacetylases - biosynthesis ; Histone Deacetylases - genetics ; Humans ; Isoenzymes - antagonists & inhibitors ; Isoenzymes - biosynthesis ; Isoenzymes - genetics ; Molecular biology ; Nervous System Diseases - drug therapy ; Nervous System Diseases - enzymology ; Nervous System Diseases - pathology ; Neurobiology ; Neurological disorders ; Neurology ; Neurosciences</subject><ispartof>Molecular neurobiology, 2009-08, Vol.40 (1), p.33-45</ispartof><rights>Humana Press Inc. 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c435t-a38d0f8094eeaeb1d3388f015c27e6c26ef958ed150bfb380fa545a4f325c6463</citedby><cites>FETCH-LOGICAL-c435t-a38d0f8094eeaeb1d3388f015c27e6c26ef958ed150bfb380fa545a4f325c6463</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12035-009-8067-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12035-009-8067-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19396637$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thomas, Elizabeth A.</creatorcontrib><title>Focal Nature of Neurological Disorders Necessitates Isotype-Selective Histone Deacetylase (HDAC) Inhibitors</title><title>Molecular neurobiology</title><addtitle>Mol Neurobiol</addtitle><addtitle>Mol Neurobiol</addtitle><description>Histone deacetylase (HDAC) inhibitors represent a promising new avenue of therapeutic options for a range of neurological disorders. Within any particular neurological disorder, neuronal damage or death is not widespread; rather, particular brain regions are preferentially affected. Different disorders exhibit distinct focal pathologies. Hence, understanding the region-specific effects of HDAC inhibitors is essential for targeting appropriate brain areas and reducing toxicity in unaffected areas. The outcome of HDAC inhibition depends on several factors, including the diversity in the central nervous system expression of HDAC enzymes, selectivity of a given HDAC inhibitor for different HDAC enzymes, and the presence or absence of cofactors necessary for enzyme function. This review will summarize brain regions associated with various neurological disorders and factors affecting the consequences of HDAC inhibition.</description><subject>Animals</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Brain - drug effects</subject><subject>Brain - enzymology</subject><subject>Brain - pathology</subject><subject>Brain research</subject><subject>Cell Biology</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Enzymes</subject><subject>Gene Expression Regulation</subject><subject>Histone Deacetylase Inhibitors</subject><subject>Histone Deacetylases - biosynthesis</subject><subject>Histone Deacetylases - genetics</subject><subject>Humans</subject><subject>Isoenzymes - antagonists & inhibitors</subject><subject>Isoenzymes - biosynthesis</subject><subject>Isoenzymes - genetics</subject><subject>Molecular biology</subject><subject>Nervous System Diseases - drug therapy</subject><subject>Nervous System Diseases - enzymology</subject><subject>Nervous System Diseases - pathology</subject><subject>Neurobiology</subject><subject>Neurological disorders</subject><subject>Neurology</subject><subject>Neurosciences</subject><issn>0893-7648</issn><issn>1559-1182</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kU9rFEEQxRtRzCb6AbzI4EH00Nr_p-cYdk12IcSDem56empix9nptatHmG_vLLsQEDwVvPrVq6IeIW84-8QZqz8jF0xqylhDLTM1nZ-RFde6oZxb8ZysmG0krY2yF-QS8ZExITirX5IL3sjGGFmvyK-bFPxQ3fsyZahSX93DlNOQHuJR3kRMuYOMixwAMRZfAKsdpjIfgH6DAUKJf6DaRixphGoDPkCZB49Qfdhurtcfq934M7axpIyvyIveDwivz_WK_Lj58n29pXdfb3fr6zsalNSFemk71lvWKAAPLe-ktLZnXAdRgwnCQN9oCx3XrO1baVnvtdJe9VLoYJSRV-T9yfeQ0-8JsLh9xADD4EdIEzpTK6a4lAv47h_wMU15XG5zgivLVWOPbvwEhZwQM_TukOPe59lx5o4xuFMMbonBHWNw8zLz9mw8tXvonibOf18AcQJwaY0PkJ82_9_1Lx5ik5M</recordid><startdate>20090801</startdate><enddate>20090801</enddate><creator>Thomas, Elizabeth A.</creator><general>Humana Press Inc</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QR</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20090801</creationdate><title>Focal Nature of Neurological Disorders Necessitates Isotype-Selective Histone Deacetylase (HDAC) Inhibitors</title><author>Thomas, Elizabeth A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c435t-a38d0f8094eeaeb1d3388f015c27e6c26ef958ed150bfb380fa545a4f325c6463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Animals</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Brain - drug effects</topic><topic>Brain - enzymology</topic><topic>Brain - pathology</topic><topic>Brain research</topic><topic>Cell Biology</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Enzymes</topic><topic>Gene Expression Regulation</topic><topic>Histone Deacetylase Inhibitors</topic><topic>Histone Deacetylases - biosynthesis</topic><topic>Histone Deacetylases - genetics</topic><topic>Humans</topic><topic>Isoenzymes - antagonists & inhibitors</topic><topic>Isoenzymes - biosynthesis</topic><topic>Isoenzymes - genetics</topic><topic>Molecular biology</topic><topic>Nervous System Diseases - drug therapy</topic><topic>Nervous System Diseases - enzymology</topic><topic>Nervous System Diseases - pathology</topic><topic>Neurobiology</topic><topic>Neurological disorders</topic><topic>Neurology</topic><topic>Neurosciences</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thomas, Elizabeth A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology Journals</collection><collection>ProQuest Science Journals</collection><collection>ProQuest Biological Science Journals</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular neurobiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thomas, Elizabeth A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Focal Nature of Neurological Disorders Necessitates Isotype-Selective Histone Deacetylase (HDAC) Inhibitors</atitle><jtitle>Molecular neurobiology</jtitle><stitle>Mol Neurobiol</stitle><addtitle>Mol Neurobiol</addtitle><date>2009-08-01</date><risdate>2009</risdate><volume>40</volume><issue>1</issue><spage>33</spage><epage>45</epage><pages>33-45</pages><issn>0893-7648</issn><eissn>1559-1182</eissn><abstract>Histone deacetylase (HDAC) inhibitors represent a promising new avenue of therapeutic options for a range of neurological disorders. Within any particular neurological disorder, neuronal damage or death is not widespread; rather, particular brain regions are preferentially affected. Different disorders exhibit distinct focal pathologies. Hence, understanding the region-specific effects of HDAC inhibitors is essential for targeting appropriate brain areas and reducing toxicity in unaffected areas. The outcome of HDAC inhibition depends on several factors, including the diversity in the central nervous system expression of HDAC enzymes, selectivity of a given HDAC inhibitor for different HDAC enzymes, and the presence or absence of cofactors necessary for enzyme function. This review will summarize brain regions associated with various neurological disorders and factors affecting the consequences of HDAC inhibition.</abstract><cop>New York</cop><pub>Humana Press Inc</pub><pmid>19396637</pmid><doi>10.1007/s12035-009-8067-y</doi><tpages>13</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0893-7648 |
| ispartof | Molecular neurobiology, 2009-08, Vol.40 (1), p.33-45 |
| issn | 0893-7648 1559-1182 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67404133 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Animals Biomedical and Life Sciences Biomedicine Brain - drug effects Brain - enzymology Brain - pathology Brain research Cell Biology Enzyme Inhibitors - therapeutic use Enzymes Gene Expression Regulation Histone Deacetylase Inhibitors Histone Deacetylases - biosynthesis Histone Deacetylases - genetics Humans Isoenzymes - antagonists & inhibitors Isoenzymes - biosynthesis Isoenzymes - genetics Molecular biology Nervous System Diseases - drug therapy Nervous System Diseases - enzymology Nervous System Diseases - pathology Neurobiology Neurological disorders Neurology Neurosciences |
| title | Focal Nature of Neurological Disorders Necessitates Isotype-Selective Histone Deacetylase (HDAC) Inhibitors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T22%3A46%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Focal%20Nature%20of%20Neurological%20Disorders%20Necessitates%20Isotype-Selective%20Histone%20Deacetylase%20(HDAC)%20Inhibitors&rft.jtitle=Molecular%20neurobiology&rft.au=Thomas,%20Elizabeth%20A.&rft.date=2009-08-01&rft.volume=40&rft.issue=1&rft.spage=33&rft.epage=45&rft.pages=33-45&rft.issn=0893-7648&rft.eissn=1559-1182&rft_id=info:doi/10.1007/s12035-009-8067-y&rft_dat=%3Cproquest_cross%3E67404133%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=214814986&rft_id=info:pmid/19396637&rfr_iscdi=true |